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Human immunodeficiency virus type 1 (HIV-1) RNA and p24 antigen concentrations were
determined in plasma samples from 169 chronically infected patients (median CD4 cell count,
140 cells/mL; range, 0–1500 cells/mL). p24 quantification involved heat-mediated immune com-
plex dissociation and tyramide signal amplification–boosted ELISA, which has a diagnostic
sensitivity similar to that of RNA quantification by a commercial polymerase chain reaction
kit. In Cox’s proportional hazard models adjusted for CD4 cell count, both RNA ( )P ! .005
and p24 ( ) levels were significant predictors of progression to AIDS. MeasurementP = .043
of p24 was superior to measurement of RNA in the model for survival ( vs.P = .032 P =
). p24 level was a significant predictor of CD4 cell decline in models adjusted for CD4 cell.19
counts and was superior or equivalent to RNA level, depending on the group analyzed.
Stratification by CD4 cell counts at baseline showed that the superiority of p24 measurement
was more pronounced at lower levels of CD4 cells (!200/mL). p24 level may be of interest as
a simple and inexpensive predictive marker of disease progression.
Virus load measurements have become indispensable in the
management of patients infected with the human immunode-
ficiency virus (HIV). Most virus is produced, and resides, in
lymphatic tissues, where routine assessment is difficult [1–3].
Virus markers in plasma, specifically the viral RNA concen-
tration, have therefore become a regularly used surrogate for
the total virus load and are predictive of decline in CD4 cells,
progression to AIDS, and survival [4–11]. In contrast, there is
an agreement that quantification of the HIV-1 load by p24
antigen tests with native serum or after acid-mediated immune
complex dissociation is unsuitable for this purpose, because
these tests are relatively insensitive and therefore have a limited
utility in clinical practice [12]. However, because many mech-
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anisms of viral pathogenicity involve proteins as the direct or
indirect mediators of disease, there is a theoretical possibility
that the concentration of viral proteins in the various body
compartments might be a better predictor of disease progres-
sion than is the particle-associated viral RNA and that the
observed inferiority of antigen testing might thus be due merely
to a technical inadequacy of the procedures used.
In previous work, we have demonstrated that p24 detection,
by use of an ELISA coupled with tyramide signal amplification
after heat-mediated immune complex dissociation [13], detects
viral protein as sensitively as polymerase chain reaction detects
viral DNA or RNA [14, 15]. The high diagnostic quality of the
amplification-boosted p24 assay was also confirmed by others
who used the procedure in a study of African children who
were vertically exposed to HIV-1 [16]. A retrospective study of
adults confirmed the high sensitivity of the procedure and dem-
onstrated that treatment-induced changes in the concentrations
of viral protein correlate very well with those in viral RNA, as
measured by the Amplicor HIV-1 monitor (version 1.0; Roche
Molecular Systems, Basel, Switzerland) with a detection limit
of 200–400 copies/mL [17]. A prospective study with real-time
analyses over 4 years among children born to HIV-positive
mothers also demonstrated a diagnostic sensitivity and speci-
ficity of p24 testing equal to those of testing for RNA and
demonstrated the suitability of this marker for monitoring an-
tiretroviral treatment [18]. These results suggest that measure-
ment of viral protein could be used as an alternative to RNA
detection for the diagnosis of HIV-1 infection and treatment
monitoring.
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In the present study, we addressed the question of whether
the p24 concentration in plasma is as predictive of clinical and
laboratory progression as is the viral RNA concentration. A
single plasma sample from each patient among a cohort rep-
resenting all stages of chronic HIV-1 infection was drawn in
1993–1994 [15]. The concentrations of viral protein and RNA
in this baseline sample were batchwise determined and related
to the ensuing changes in CD4 cell count, progression to clinical
AIDS, and survival.
Patients and Methods
Patients and samples. The 169 patients (131 men and 38
women) were derived from a group of 245 patients from the Zurich
center of the Swiss HIV Cohort Study, whose plasma was used for
a comparison of various antigen test procedures between 5 January
1993 and 27 May 1994 [15]. The study design and recent results
of the Swiss HIV Cohort Study have been published elsewhere
[19–21]. In brief, enrollment of HIV-1–infected persons aged >16
years into the cohort is independent of disease stage or degree of
immunosuppression, and information is collected prospectively ac-
cording to standardized criteria on structured forms at registration
and at follow-up visits, which are scheduled at 6-month intervals.
Routine laboratory results from intermediate visits are included.
For the present study, a single EDTA-anticoagulated plasma spec-
imen from each patient was analyzed, and the sole inclusion cri-
terion was whether sufficient material was available for testing. In
March 1998, clinical and laboratory follow-up data from the 169
patients were extracted from the database of the Swiss HIV Cohort
Study, which included information up to 9 February 1998. Clinical
progression to AIDS was strictly defined on the basis of AIDS
indicator diseases [22].
Among the 169 patients, the risk factors for contracting HIV-1
were homosexual contact (51%), injection drug use (31%), hetero-
sexual contact (14%), or unknown (4%). Participants with a history
of injection drug use who also had heterosexual contacts were clas-
sified as injection drug users. Fifty-nine (35%) of the patients were
in CDC disease stage A, 49 (29%) in stage B, and 61 (36%) in stage
C. The median CD4 cell count at baseline was 140 cells/mL (range,
0–1500 cells/mL), with the 10th, 25th, 75th, and 90th percentiles at
10, 30, 312.5, and 510 cells/mL, respectively. Ninety (53.3%) of the
patients were receiving no antiretroviral treatment, 69 (40.8%) were
being treated with a single nucleoside analogue reverse-transcrip-
tase inhibitor, and 10 (5.9%) were receiving a combination of 2
nucleoside analogue reverse-transcriptase inhibitors. No patient
was receiving treatment with protease inhibitors (PIs) at baseline.
Quantification of viral components. Viral protein p24 concen-
tration in heat-denatured plasma was assessed by batch analysis
of blinded samples. In brief, 100 mL of plasma was diluted with
500 mL of 0.5% Triton X-100 in 1.5-mL Eppendorf tubes, subjected
to 5 min of heat denaturation at 1007C on a Techne (Cambridge,
UK) dry heat block, and tested in duplicate with the NEN/Du
Pont HIV-1 Core Profile ELISA in combination with the ELAST
ELISA Amplification System (both from NEN Life Science Prod-
ucts, Geneva, Switzerland), as described elsewhere [15]. The re-
action product was quantified on a Dynatech MR5000 ELISA
reader (Microtech Produkte, Embrach, Switzerland). Samples with
protein concentrations above the assay range were retested by use
of kinetic analysis with the Quanti-Kinc Detection System (Tib
Molbiol, Genoa, Italy). This permitted quantification in a range
of ∼400–6,250,000 fg/mL with a single sample dilution.
HIV-1 RNA concentrations were determined by batch analysis
in plasma samples that had been frozen at 2707C no later than 4
h after the sample was drawn and had not been thawed before
testing. For testing, the Amplicor HIV monitor, version 1.0 (Roche
Molecular Systems), with a detection limit of 200–400 copies/mL,
was used.
Data analysis. The StatView 5.0 program for Macintosh (SAS
Institute, Cary, NC) was used for plotting figure 1 and for calcu-
lating this figure’s linear and locally weighted regression curves, by
means of a locally weighted scatter plot smoother (lowess) based
on a least-squares fit, with a tension of 66%.
For analysis of predictive values, data were analyzed by use of
SAS software, version 6.11 (SAS Institute). Differences between
groups were analyzed by x2 tests, analysis of variance (ANOVA),
or t tests.
Prediction of CD4 cell slopes. Individual CD4 cell slopes were
determined by use of linear regressions of CD4 cell counts
( L) for all patients with >2 CD4 cell measurements over6cells 3 10 /
time ( ). To control for the possible effects of antiretroviraln = 136
therapies on the evolution of CD4 cell values, several subgroups
of CD4 cell values were analyzed separately: (1) all available CD4
cell values with dates greater than or equal to the baseline evalu-
ation; (2) CD4 cell values restricted to dates before a therapy in-
cluding a PI was started for an individual patient; (3) CD4 cell
values restricted to dates before any antiretroviral therapy was
started; and (4) CD4 cell values restricted to a period after baseline
with unchanged antiretroviral therapy for 16 months, antiretroviral
therapy discontinued >2 months before baseline, or never having
received antiretroviral therapy. Associations between individual
CD4 cell slopes and baseline values of p24 antigen and plasma
HIV RNA level were compared by use of Spearman’s rank cor-
relation coefficients.
Prediction of clinical progression. Kaplan-Meier analysis and
Cox’s proportional hazards regression models were used to analyze
the risk of progression to a first diagnosis of AIDS or death across
quartiles of baseline plasma levels for p24 antigen and HIV RNA
[20, 21]. We measured times until either the attainment of the re-
spective end point or the date of the most recent follow-up visit.
The analyses of progression to clinical AIDS were restricted to 108
patients in clinical stage A or B. To compare the predictive values
of plasma p24 protein and plasma HIV RNA levels, these were
entered in separate proportional hazard models that were adjusted
for disease stage, transmission category, sex, age in increments of
10 years, and CD4 cell count. CD4 cell counts (11 [added to avoid
log0 in patients with no detectable CD4 cells]) were log-transformed
and entered as a continuous variable. In addition, beginning PI-
containing therapy was entered as a time-dependent covariate. Re-
sults are presented as risk ratios with 95% confidence intervals.
Proportional hazard assumptions were tested on the basis of
Schoenfeld residuals [23].
Results
Up to February 1998, the 169 patients (131 men and 38
women) selected for this study contributed 431 person-years of
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Figure 1. Viral RNA and p24 concentrations in relation to CD4 cell count. Semilogarithmic and double-logarithmic representations are given
to make changes at very low CD4 cell counts more visible. Narrow lines represent linear regression; boldface lines represent lowess regression
with 66% tension. One CD4 cell count of 1500 was treated as an outlier and was excluded from analysis. Undet., undetectable.
follow-up (median, 2.7 years; range, 0.09–4.9 years). Eighty-
three patients died. At baseline and during follow-up, a total
of 1291 CD4 cell counts were recorded, with a median of 7
determinations (range, 1–29 determinations) per patient. Base-
line viral RNA and protein concentrations were determined
batchwise in a blinded fashion from 169 plasma samples (1 per
patient) collected in 1993–1994. All samples had detectable viral
protein, and all but 2 were positive for viral RNA. For quan-
titative evaluations, the copy number of the 2 RNA-negative
samples (both from patients in stage A2 with 600 and 1000 fg/
mL of viral protein, respectively) was set to 100/mL. Expressed
as quartiles, median baseline RNA concentrations were 3293
copies/mL for quartile 1; 29,262 copies/mL for quartile 2;
83,389 copies/mL for quartile 3; and 204,558 copies/mL for
quartile 4. The respective concentrations of p24 antigen were
1700 fg/mL for quartile 1; 15,000 fg/mL for quartile 2; 31,000
fg/mL for quartile 3; and 200,500 fg/mL for quartile 4. For the
108 patients free of clinical AIDS at baseline, the corresponding
values for quartiles 1–4 were 2394, 23,766, 82,933, and 175,155
copies/mL, respectively, for RNA and 1550, 16,400, 41,500 and
149,000 fg/mL, respectively, for viral p24 antigen.
Viral protein and RNA concentrations at baseline were sig-
nificantly correlated in the 169 samples (Spearman ;R = .525
). Correlations were similar for patients in stages A–CP ! .0001
(as defined by the CDC 1993 classification) [22], as well as in
CD4 cell categories 1–3 (data not shown). Mean viral RNA
levels, as shown by the lowess regression curve, increased little
as CD4 cell counts went down to 400 but rose with an increasing
angle when CD4 cell counts dropped below this mark (figure
1A). Linear regression showed a highly significant correlation
with CD4 cell count (Spearman ; ), al-R = 2.578 P ! .0001
though the curve did not fit well with lowess regression. A log
representation of the CD4 cell counts, which gives a better
resolution in the range of low counts, showed that the mean
RNA concentration, as assessed by lowess regression, reached
a plateau at ∼1.5 logs (CD4 cell count, 30 cells/mL) and did
not increase any further at lower CD4 cell counts (figure 1B).
Mean p24 levels increased very gradually from early to late
JID 2000;181 (April) Predictive Value of HIV-1 p24 and RNA 1283
Table 1. Prediction of CD4 lymphocyte depletion by viral p24 or RNA con-
centrations at baseline.
Variable
Slopes derived from
all CD4 counts
Slopes derived from
CD4 counts prior to
PI therapy
No. of patients 136 136
No. of CD4 cell counts (total/patient) 1258 929
Median (range) 8 (2–29) 6 (2–22)
Mean CD4 slope (cells/year) 217.1 236.6
Median slope (Q1, Q3) 28 (237, 16) 222 (261, 0)
Spearman rank correlation R (P)
CD4 slope vs. baseline CD4 2.074 (.39) 2.19 (.024)
CD4 slope vs. baseline p24 2.21 (0.016) 2.30 (.001)
CD4 slope vs. baseline RNA 2.12 (.158) 2.19 (.023)
Spearman R (P); baseline
(CD4 = 200; n = 71)
CD4 slope vs. baseline CD4 .092 (.45) 2.12 (.31)
CD4 slope vs. baseline p24 2.35 (.003) 2.36 (.002)
CD4 slope vs. baseline RNA 2.27 (.020) 2.28 (.017)
Spearman R (P); baseline
(CD4 1 200; n = 65)
CD4 slope vs. baseline CD4 2.18 (.15) 2.033 (.79)
CD4 slope vs. baseline p24 2.13 (.28) 2.32 (.010)
CD4 slope vs. baseline RNA 2.10 (.42) 2.32 (.009)
Univariate linear regression coefficient (P)
CD4 slope vs. log CD4 29.52 (.29) 22.2 (.023)
CD4 slope vs. log p24 215 (.019) 219.3 (.005)
CD4 slope vs. log RNA 27.8 (.24) 211.7 (.10)
Multivariate linear regression (P)
CD4 slope vs. log p24 216.6 (.010) 222.5 (.001)
and log CD4 213.4 (.14) 227.4 (.004)
CD4 slope vs. log RNA 214.9 (.049) 226.2 (.001)
and log CD4 219.7 (.057) 240 (.001)
stages of disease, and the lowess regression curve followed the
linear regression curve very closely (linear ;regression = 2.183
). p24 concentrations in early immunodeficiency (CD4P = .0178
cell count, 200–500 cells/mL), compared with the cross-sectional
distributions, tended to be relatively higher than the corre-
sponding RNA levels, whereas the reverse situation was ob-
served at low CD4 cell counts. In consequence, the slope of
the linear regression curve for p24 was less steep than that for
RNA, and the lowess regression curve was without the distinct
terminal increase seen with RNA at very low CD4 cell counts
(figure 1C). Peak average p24 levels were achieved in patients
with CD4 cell counts of 30. Remarkably, at even lower CD4
cell counts, these levels dropped again and were negatively cor-
related with the CD4 cell count (ANOVA, ; figureP = .0308
1D). Antiretroviral treatment with 1 or 2 nucleoside analogue
reverse-transcriptase inhibitors did not significantly change
these cross-sectional virus load distributions (not shown).
Predictive values. To assess the predictive values of viral
protein and RNA concentrations, follow-up data, including at
least 1 further CD4 cell count and assessment of clinical stage,
were available for 136 of the patients from the Swiss HIV Co-
hort Study database, with a median observation period of 2.7
years (range, 0.09–4.9 years). Fifty-nine patients (35%) had clin-
ical AIDS at baseline, and another 35 patients (21%) developed
AIDS during follow-up. Eighty-three patients (49%) died dur-
ing follow-up. The median number of CD4 cell counts available
for calculation of slopes, including the baseline value, was 8
per patient (range, 2–29 CD4 cell counts).
Prediction of CD4 cell slopes. Baseline concentrations of
CD4 cells, p24, and RNA were related by various methods to
the ensuing CD4 cell slopes available from 136 patients, as
shown in table 1. For calculation of the CD4 cell slopes, either
all available CD4 cell counts after baseline or only those before
onset of treatment with a PI were included in the analyses. In
both groups and by all analyses, the baseline concentrations of
p24 were significantly correlated with the ensuing CD4 cell
slopes, except for patients with baseline CD4 cell counts 1200
when analyzed by Spearman rank correlation. When the slopes
were restricted to CD4 cell counts determined during the period
before PI therapy, correlations of p24 antigen and HIV RNA
levels with the CD4 cell slope were markedly better in most
analyses, compatible with the observation that PI-containing
drug combinations are capable of reversing the depletion in
CD4 cells. The slopes before PI therapy, therefore, represent
the natural course of CD4 cell depletion better than do those
derived from all available CD4 cell counts. In theory, the period
free of any therapy would be even more suitable. However,
there were only 35 patients for this analysis, and there were no
significant correlations (not shown). Similarly, when CD4 cell
counts in a period of unchanged treatment were analyzed for
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Figure 2. Kaplan-Meier analysis of quartiles of viral RNA and p24 concentrations with respect to survival and progression to clinical AIDS,
stratified for baseline CD4 cell count. A–D, Fraction progressing to death among 169 patients; A and B, 83 patients with CD4 cell counts 1140/
mL median; C and D, 86 patients with CD4 cell counts <140/mL. E–H, Progression to clinical AIDS among 108 patients; E and F, 54 patients
with CD4 cell counts 1255/mL median; G and H, 54 patients with CD4 cell counts <255/mL.
75 available patients, there were no significant correlations with
p24 or RNA levels (not shown).
p24 was a better predictor of CD4 cell depletion than was
RNA in all Spearman analyses, except for patients with CD4
cell counts 1200, for whom the predictive values of RNA and
p24 antigen were about equal. p24 level prevailed over RNA
level in univariate linear regression analyses. In multivariate
analysis, which also adjusted for the baseline CD4 cell count,
p24 level was superior to RNA level with the slopes derived
from all CD4 cell counts and equal to RNA level for slopes
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Table 2. Multivariate Cox proportional hazard regression of survival
(169 patients, 83 events).
Variable
Risk ratio
(95% CI) P
Risk ratio
(95% CI) P
Log CD4 at baseline 0.334
(0.240–0.465)
.0001 0.397
(0.279–0.566)
.0001
CDC stage C at baseline 2.544
(1.488–4.349)
.0006 2.675
(1.563–4.580)
.0003
Age, per 10 years 1.474
(1.187–1.830)
.0004 1.427
(1.161–1.753)
.0007
PI-containing therapya 0.116
(0.029–0.457)
.0021 0.127
(0.033–0.496)
.003
HIV-1 p24
Quartile 1 1 .032
Quartile 2 1.554
(0.698–3.460)
Quartile 3 2.013
(0.931–4.350)
Quartile 4 2.877
(1.351–6.130)
HIV-1 RNA
Quartile 1 1 .19
Quartile 2 1.572
(0.662–3.736)
Quartile 3 2.231
(0.989–5.031)
Quartile 4 2.293
(0.976–5.385)
NOTE. Model was adjusted for all variables listed. CI, confidence interval;
PI, protease inhibitor; HIV-1, human immunodeficiency virus type 1.
a Entered as time-dependent variable.
from before PI treatment. In conclusion, p24 level was a sig-
nificant predictor of CD4 cell decline in models adjusted for
CD4 cell counts and was superior or equivalent to RNA level
when all available CD4 cell values or CD4 cell values from
dates before the commencement of PI therapy were used. Strat-
ification by CD4 cell counts at baseline (<200 vs. 1200) showed
that the superiority of p24 level was more pronounced at lower
CD4 cell counts. The CD4 cell count at baseline was a signif-
icant covariate in some but not all groups.
Prediction of survival. Because baseline CD4 cell counts
were likely to influence the progression rate, Kaplan-Meier
curves were stratified for CD4 cell counts (figure 2). Among 83
patients with CD4 cell counts above the median of 140/mL, the
curves were similar for p24 (figure 2A) and RNA levels (figure
2B). For p24 levels, the courses of quartile 1 compared with
quartile 2 and of quartile 3 compared with quartile 4 were
similar, whereas for RNA levels, quartile 1 and quartile 4 moved
separately (although not differently from quartile 1 or, respec-
tively, quartile 4 of p24), but quartile 2 ran together with quar-
tile 3. Among the 86 patients with CD4 cell counts <140/mL,
both markers showed little discrimination regarding progres-
sion, and all quartile curves rose steeply and in 1 group during
at least the first year of follow-up. For further analysis, p24
was compared with RNA level in separate multivariate Cox
proportional hazard models, which were adjusted for CD4 cell
count, disease stage C, age, and starting a PI-containing regi-
men (table 2). Transmission category and sex did not reach
statistical significance in univariate and multivariate analyses
and therefore were dropped from the final model. The results
of this analysis indicated that viral protein level, but not viral
RNA level, was a significant independent prognostic factor of
survival ( vs. ).P = .032 P = .19
Prediction of progression to clinical AIDS. Among the 54
patients with baseline CD4 cell counts above the median of 255
cells/mL, the Kaplan-Meier curves of p24 and RNA levels were
again similar (figure 2E and 2F). Quartile 4 of RNA was better
separated from the other quartiles than was quartile 4 of p24,
which was not different from quartile 3. In the 54 patients with
CD4 cell counts <255/mL, p24 level again showed the pattern
of quartile 1 moving with quartile 2 and quartile 4 moving with
quartile 3; on the other hand, for RNA level, there was a very
clear separation of quartile 1 and quartile 4 from each other
and, for both of them, from quartile 2 and quartile 3 (figure
2G and 2H). Log-rank testing (not stratified for CD4 cell count)
clearly showed RNA level to be superior to p24 level (table 3).
Multivariate Cox proportional hazard regression analyses in-
dicated that clinical progression correlated highly significantly
with baseline RNA levels but only weakly with p24 levels. De-
spite an overall significant correlation ( ), none of theP = .043
individual p24 quartiles had risk ratios that excluded the value
1. In agreement with figure 2, there also appeared to be no
increase in the risk ratios of quartiles 3 and 4 of p24.
Discussion
There is ample evidence that the concentration of viral RNA
in serum or plasma is predictive of disease progression. A cor-
relation of baseline RNA levels with clinical progression and/
or survival was found during the first 6–12 months after se-
roconversion [9, 24, 25] among both patients who were
asymptomatically infected [26] and patients with or without
symptoms who had relatively well-preserved numbers of CD4
cells [10, 27, 28]. In more advanced disease, the predictive value
of RNA was less evident, but the importance of CD4 cell count
increased [29–32]. Some of these studies also assessed the pre-
dictive value of p24 antigen [28, 32–34]. In all, p24 was less
frequently detectable than was viral RNA. In 2 studies, p24
was never significant when included together with RNA into
multivariate proportional hazards models [28, 32]. However, in
2 studies investigating patients early after seroconversion, the
detectability of p24 antigen was found to be a stronger predictor
of AIDS than was RNA concentration [34], even when analyzed
by multivariate Cox proportional hazard models [33].
In the present study, we compared viral RNA and p24 con-
centrations, as measured by a method combining heat-medi-
ated immune complex dissociation with signal amplification–
boosted ELISA, in a single plasma sample taken in 1993–1994,
before the availability of highly active antiretroviral treatment,
from patients at various stages of chronic HIV infection. The
advantages of this antigen detection consist in its high analytical
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Table 3. Multivariate Cox proportional hazard regression of pro-
gression to AIDS (108 patients free of AIDS at baseline, 35 events).
Variable
Risk ratio
(95% CI) P
Risk ratio
(95% CI) P
Log CD4 at baseline 0.245
(0.136–0.441)
.0001 0.294
(0.156–0.552)
.0001
CDC stage B at baseline 2.402
(1.058–5.449)
.036 2.352
(0.979–5.646)
.056
Age, per 10 years 1.137
(0.826–1.566)
.43 1.128
(0.826–1.541)
.45
PI-containing therapya 2.480
(0.536–11.484)
.25 2.710
(0.603–12.184)
.19
HIV-1 p24
Quartile 1 1 .043
Quartile 2 0.749
(0.167–3.348)
Quartile 3 2.556
(0.770–8.480)
Quartile 4 2.411
(0.705–8.249)
HIV-1 RNA
Quartile 1 1 .0042
Quartile 2 2.082
(0.330–13.159)
Quartile 3 5.488
(1.176–25.617)
Quartile 4 6.887
(1.512–31.360)
NOTE. Model was adjusted for all variables listed. CI, confidence interval;
PI, protease inhibitor; HIV-1, human immunodeficiency virus type 1.
a Entered as time-dependent variable.
sensitivity and broad quantification range (0.5–6400 pg/mL)
and its irreversibly releasing all antigen from immune com-
plexes. This sets the procedure apart from acid- or base-me-
diated immune complex dissociation, in which the pH neu-
tralization that has to be achieved before the actual antigen
test can be done may lead to a partial recomplexation of the
antigen, resulting in individually unpredictable underdetection
[13].
An important advantage of the procedure compared with
quantification of viral RNA is its simplicity and its considerably
lower cost. In Switzerland, p24 quantification costs only 18%
of the price of viral RNA quantification. Although samples
from both early and advanced disease stages were investigated
in the present study, there were few patients with CD4 cell
counts 1500/mL, and the study cohort was representative of the
moderately advanced and more advanced stages of disease. The
results show that p24 level at baseline was a significant predictor
of CD4 cell decline in models adjusted for CD4 cell counts and
was superior or equivalent to RNA level, superior especially
at CD4 cell counts <200 (table 1). We also found that p24
concentration, but not RNA concentration, was a significant
independent predictor of survival in multivariate Cox regression
analysis (table 2). However, RNA level was a highly significant
independent predictor of progression to AIDS, whereas p24
level was only weakly significant (table 3).
The progressive loss of CD4 cells is the basis for the occur-
rence of opportunistic infections or tumors (signs and symp-
toms of clinical AIDS), which finally lead to death. Because
baseline p24 levels correlated well with depletion rates of CD4
cells, one would expect that p24 level would equally well predict
clinical progression and survival. We are currently unable to
explain conclusively why p24 level should be a better predictor
of survival and RNA level a better predictor of clinical pro-
gression. It is particularly puzzling that viral RNA level, which
is markedly inferior to p24 level in prediction of the CD4 cell
slope in patients with CD4 cell counts <200 (table 1), should
in this very group be superior to p24 level in predicting pro-
gression to AIDS, as suggested by the Kaplan-Meier analysis
(figure 2G and 2H).
This discrepancy suggests that—independent of CD4 cell de-
pletion—there could be an additional mechanism that would
account for both a high viral RNA (but not p24) load in plasma
and an increased progression to AIDS. Histopathologic anal-
ysis has shown an almost complete destruction of the lymph
node architecture and fine structure in advanced HIV infection,
and it is assumed that this loss of functional structure contrib-
utes significantly to the immunodeficiency [35]. One particular
feature of this destruction is the loss of the follicular dendritic
cell network, which is known to serve as a kind of filter that
retains the particles produced in the lymphatics [1, 2, 35, 36].
Recent studies have indicated a virus half-time of only a few
minutes [37]. A considerable fraction of particles should thus
be eliminated while they are entangled within the follicular den-
dritic cell network. When the network is destroyed, significantly
more particles would reach the bloodstream, thus increasing
the viral RNA load in plasma. In contrast, p24 antigen should
pass freely through the network, owing to its small size and its
higher resistance to degradation. The destruction of the follic-
ular dendritic cell network would thus not be mirrored by a
concomitant increase in plasma antigenemia. A discrepancy of
p24 and viral RNA concentrations in patients with very low
CD4 cell counts is indeed seen in figure 1 and is particularly
manifest when only the untreated patients are compared (not
shown).
The increasing RNA concentration in advanced disease could
thus reflect that not only the CD4 cells but also the lymph node
structure is destroyed and therefore could indicate a particularly
severe status of immunodeficiency, which renders the patient
highly vulnerable to AIDS-defining illnesses. The fact that the
virus load, as measured by both p24 and RNA levels, appears
to be of no importance during the last 1–2 years before death
(i.e., in the very period during which AIDS is most likely to
occur), as shown by the Kaplan-Meier analyses of figure 2C
and 2D, further supports the interpretation that it is not a
higher production of virus particles that is responsible for rapid
clinical progression in this advanced stage.
Taken together, the present study provides preliminary evi-
dence that HIV p24 concentrations, as detected by this signif-
icantly improved procedure, may be a valuable predictive
marker for certain aspects of disease progression. Larger studies
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with more homogenous patient populations at defined stages
of CD4 cell deficiency are now needed to resolve the inconsis-
tencies discussed above. If these results can be confirmed and
perhaps even improved, this simple, inexpensive, and easily au-
tomatable procedure, which does not require cumbersome sam-
ple transport and pretreatment procedures, might contribute to
improvements in the monitoring and treatment of HIV infec-
tions worldwide.
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